Publication | Open Access
Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina
57
Citations
29
References
2021
Year
Cardiometabolic RiskHigh TgLow Hdl CholesterolHyperlipidemiaStable AnginaCoronary Artery DiseasePublic HealthCardiovascular Disease PathogenesisAtherosclerosisCardiac ImagingDyslipidemiaLipid DisorderCardiovascular ImagingPercutaneous Coronary InterventionCardiovascular EpidemiologyHealth PolicyTotal CholesterolCardiovascular Disease Risk AssessmentEpidemiologyCoronary Heart DiseaseCardiovascular DiseaseDiabetesCardiovascular Risk FactorsMedicine
We assessed whether high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels, expressed by an increased TG/HDL-C ratio, predict coronary atherosclerotic disease (CAD) outcomes in patients with stable angina. We studied 355 patients (60 ± 9 years, 211 males) with stable angina who underwent coronary computed tomography angiography (CTA), were managed clinically and followed for 4.5 ± 0.9 years. The primary composite outcome was all-cause mortality and non-fatal myocardial infarction. At baseline, the proportion of males, patients with metabolic syndrome, diabetes and obstructive CAD increased across TG/HDL-C ratio quartiles, together with markers of insulin resistance, hepatic and adipose tissue dysfunction and myocardial damage, with no difference in total cholesterol or LDL-C. At follow-up, the global CTA risk score (HR 1.06, 95% confidence interval (CI) 1.03-1.09, P = 0.001) and the IV quartile of the TG/HDL-C ratio (HR 2.85, 95% CI 1.30-6.26, P < 0.01) were the only independent predictors of the primary outcome. The TG/HDL-C ratio and the CTA risk score progressed over time despite increased use of lipid-lowering drugs and reduction in LDL-C. In patients with stable angina, high TG and low HDL-C levels are associated with CAD related outcomes independently of LDL-C and treatments.Trial registration. EVINCI study: ClinicalTrials.gov NCT00979199, registered September 17, 2009; SMARTool study: ClinicalTrials.gov NCT04448691, registered June 26, 2020.
| Year | Citations | |
|---|---|---|
Page 1
Page 1